SRDX News and Press, Surmodics Inc. From 11/04/20

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 fourth quarter ended September 30, 2020. Summary of Fourth Quarter and Recent Highlights Revenu...

Surmodics is in the early stages of an extended growth period in our view, with high conversion potential from their pipeline. The company has key differentiators within its medical devices and IVD segments, with potential to generate long-tailed returns in manufacturing and distribut...

Webcast is Live at 4 p.m. (CT) Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2020 conference call on Wedn...

Surmodics (SRDX) has received FDA 510(k) clearance for its Pounce Thrombus Retrieval System for the treatment of peripheral artery disease ((PAD)). The Pounce Thrombus is intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature. PAD is a seriou...

Next-generation technology provides easy, effective clot removal from peripheral arterial vasculature Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food...

The following slide deck was published by Surmodics, Inc. in conjunction with their 2020 Q3 earnings Read more ...

Surmodics, Inc. (SRDX) Q3 2020 Earnings Conference Call August 5, 2020 17:00 ET Company Participants Tim Arens - Vice President, Finance & Chief Financial Officer Gary Maharaj - Chief Executive Officer Conference Call Participants Jim Sidoti - Sidoti & Company Brook...

Surmodics (NASDAQ: SRDX ) : Q3 Non-GAAP EPS of $0.21 beats by $0.02 ; GAAP EPS of $0.18 beats by $0.08 . More news on: Surmodics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Device designed to treat below-the-knee vessels from the radial arteries with industry’s longest (250 cm) working length Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has recei...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 third quarter ended June 30, 2020. Summary of Third Quarter and Recent Highlights Revenue of $26.9 mill...